2 weeks Ago By ABMN Staff
Bank of New York Mellon Corp acquired a new position in Pro-Dex, Inc. ( NASDAQ:PDEX – Free Report ) during the fourth quarter, HoldingsChannel.com reports.
The fund acquired 4,319 shares of the medical instruments supplier’s stock, valued at approximately $202,000. Several other institutional investors have also added to or reduced their stakes in the stock. Ritholtz Wealth Management acquired a new position in shares of Pro-Dex in the 4th quarter worth approximately $572,000.
FMR LLC lifted its holdings in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares during the period.
Geode Capital Management LLC grew its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the period.
Finally, JPMorgan Chase & Co. raised its position in shares of Pro-Dex by 2.2% in the 3rd quarter.
JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares in the last quarter. 15.
28% of the stock is currently owned by institutional investors. Insider Buying and Selling at Pro-Dex In related news, Director Raymond E. Cabillot sold 835 shares of the company’s stock in a transaction dated Thursday, January 23rd.
The shares were sold at an average price of $42.00, for a total value of $35,070.00.
Following the sale, the director now owns 334,646 shares in the company, valued at $14,055,132. This represents a 0.25 % decrease in their position.
The transaction was disclosed in a legal filing with the SEC, which is available at this link . Over the last quarter, insiders sold 47,475 shares of company stock valued at $2,186,594. Company insiders own 47.
50% of the company’s stock. Analyst Ratings Changes Read Our Latest Stock Analysis on PDEX Pro-Dex Stock Performance NASDAQ:PDEX opened at $48.23 on Friday.
The firm has a market capitalization of $157.28 million, a P/E ratio of 24.00 and a beta of 0.
68. Pro-Dex, Inc. has a twelve month low of $16.
84 and a twelve month high of $59.60. The company has a fifty day moving average of $40.
21 and a 200-day moving average of $39.99. The company has a quick ratio of 1.
44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33.
Pro-Dex ( NASDAQ:PDEX – Get Free Report ) last released its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.
38 by $0.23. Pro-Dex had a net margin of 11.
06% and a return on equity of 21.68%. As a group, sell-side analysts anticipate that Pro-Dex, Inc.
will post 2 EPS for the current year. Pro-Dex Company Profile ( Free Report ) Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Further Reading Want to see what other hedge funds are holding PDEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pro-Dex, Inc. ( NASDAQ:PDEX – Free Report ).
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter ..
